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ABSTRACT
Background
Very little is known about the immunodominance patterns of HIV-1-specific T cell responses
during primary HIV-1 infection and the reasons for human lymphocyte antigen (HLA)
modulation of disease progression.
Methods and Findings
In a cohort of 104 individuals with primary HIV-1 infection, we demonstrate that a subset of
CD8
þ T cell epitopes within HIV-1 are consistently targeted early after infection, while other
epitopes subsequently targeted through the same HLA class I alleles are rarely recognized.
Certain HLA alleles consistently contributed more than others to the total virus-specific CD8
þ T
cell response during primary infection, and also reduced the absolute magnitude of responses
restricted by other alleles if coexpressed in the same individual, consistent with immunodomi-
nation. Furthermore, individual HLA class I alleles that have been associated with slower HIV-1
disease progression contributed strongly to the total HIV-1-specific CD8
þT cell response during
primary infection.
Conclusions
These data demonstrate consistent immunodominance patterns of HIV-1-specific CD8
þT cell
responses during primary infection and provide a mechanistic explanation for the protective
effect of specific HLA class I alleles on HIV-1 disease progression.
The Editors’ Summary of this article follows the references.
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The majority of individuals infected with HIV-1 develop an
acute viral syndrome within 7–21 days of infection, charac-
terized primarily by fever, lymphadenopathy, and cutaneous
rash in the presence of very high levels of HIV-1 replication
[1,2]. Both innate and adaptive immune responses, including
natural killer cell responses, HIV-1-speciﬁc CD4
þand CD8
þ T
cell responses, and neutralizing antibodies have been asso-
ciated with the subsequent resolution of the clinical
symptoms and the decline of HIV-1 RNA levels to so-called
viral set point levels. In particular, the ﬁrst appearance of
HIV-1-speciﬁc CD8
þ T cells in the peripheral blood has been
shown to be temporally associated with the initial decline of
HIV-1 viremia during primary infection [3,4], suggesting a
crucial role of these early virus-speciﬁc T cells in the control
of viral replication. This is further supported by the lack of
decline in viral replication in simian immunodeﬁciency virus-
infected macaques depleted of CD8
þ lymphocytes [5–7] and
the selection of viral strains containing sequence variations
within targeted CD8
þ T cell epitopes during this early phase
of infection [8–11], indicative of HLA class I-restricted
immune selection pressure on the virus.
Despite this presumed immune-mediated decline in acute
viremia, HIV-1-speciﬁc CD8
þ T cell responses in primary
infection are of lower magnitude and more narrowly directed
against a limited number of epitopes than are HIV-1-speciﬁc
CD8
þ T cell responses detected in chronic infection [12–15],
indicating that the quality and speciﬁcity, rather than the
quantity, of virus-speciﬁc CD8
þ T cell responses may be
associated with the initial control of viral replication [16–20].
However, very little is known about the individual epitopes
targeted during primary HIV-1 infection and their immuno-
dominance pattern, as these studies are complicated by the
high HLA class I diversity in humans, requiring large
numbers of participants with primary infection to draw
meaningful conclusions. To date, studies of the speciﬁcity of
HIV-1-speciﬁc CD8
þ T cell responses during primary HIV-1
infection have been limited in size, focused on individuals
expressing speciﬁc HLA alleles of interest, or assessed the
protein speciﬁcity of these CD8
þ T cells without determining
the individual targeted epitopes in the context of the
restricting HLA class I molecules [12–15,21–25].
Here, we describe the characterization of HIV-1-speciﬁc
CD8
þ T cell responses on the single-epitope level in a cohort
of 104 individuals identiﬁed during primary HIV-1 infection.
The aim of the study was to identify the immunodominant
CD8
þ T cell epitopes within HIV-1 that are targeted during
primary HIV-1 infection, and to assess the contribution of
CD8
þT cell responses restricted by the individual HLA class I
molecules to the total virus-speciﬁc CD8
þ T cell response
early in infection.
Methods
Study Participants
A total of 104 HIV-1-infected individuals were enrolled in
this study at the Massachusetts General Hospital in Boston,
Massachusetts, United States, and a private medical clinic
(Jessen-Praxis) in Berlin, Germany. Of this group, 69 (66%)
individuals were identiﬁed during acute HIV-1 infection, as
deﬁned by either a negative HIV-1 p24 ELISA or an evolving
HIV-1 Western blot (fewer than three bands), and the
remaining 35 (34%) were identiﬁed within the ﬁrst 6 mo of
HIV-1 infection, as deﬁned by a negative HIV-1 p24 ELISA
during the past 6 mo or a negative detuned HIV-1 ELISA at
the time of enrollment. The majority of study participants
were men who have sex with men (98 [94%]) and individuals
of Northern European descent (83 [80%]). The average viral
load at presentation was 3,527,188 HIV-1 RNA copies/ml
(range 50–84,200,000 copies) and the average CD4
þ T cell
count was 520 cells/ll (range 42–1,334). The majority of
individuals (88 [85%]) initiated HAART during primary
infection. The assessment of HIV-1-speciﬁc CD8
þ T cell
responses was performed on frozen peripheral blood mono-
nuclear cell (PBMC) samples collected 8 wk (6 10 d) following
initial presentation. This time point was chosen because
previous studies had demonstrated that a substantial subset
of individuals with acute HIV-1 infection have no detectable
or only very weakly detectable HIV-1-speciﬁc CD8
þ T cell
responses at presentation, and that the HAART-induced
decline in virus-speciﬁc T cell responses occurs after 8 wk of
treatment in individuals treated with HAART during acute or
early HIV-1 infection [12]. The study was approved by the
respective institutional review boards and was conducted in
accordance with human experimentation guidelines of the
Massachusetts General Hospital, and all study participants
provided informed consent prior to enrollment in the study.
HLA Typing
High- and intermediate-resolution HLA class I typing was
performed by sequence-speciﬁc PCR according to standard
procedures. DNA was extracted from PBMCs using the
Puregene DNA Isolation Kit for blood (Gentra Systems,
Minneapolis, Minnesota, United States).
IFN-c Enzyme-Linked Immunosorbent Spot Assay
HIV-1-speciﬁc CD8
þ T cell responses were quantiﬁed by
IFN-c enzyme-linked immunosorbent spot (ELISPOT) assay,
using a panel of 173 peptides corresponding to described
optimal clade B cytotoxic T lymphocyte epitopes [26]. PBMCs
were plated at 100,000 cells per well with peptides at a ﬁnal
concentration of 10
 5 molar in 96-well plates and processed
as described [12]. PBMCs were incubated with media alone
(negative control) or PHA (positive control). The number of
speciﬁc IFN-c secreting T-cells were counted using an
automated ELISPOT reader (AID, Strassberg, Germany),
calculated by subtracting the average negative control value
and expressed as spot-forming cells (SFCs)/10
6 input cells.
Negative controls were always 30 SFCs/10
6 input cells or
fewer. A response was considered positive at 50 SFCs/10
6
input cells or more and when the total number of spots were
at least three times greater than the mean number of spots in
the negative control wells.
Hazard Ratios for Disease Outcomes
The hazard ratios (HRs) for the various HLA alleles were
determined previously using Cox model analyses [27–30].
Brieﬂy, 1,217 HIV-1-infected individuals for whom the dates
of seroconversion were known were derived from four
cohorts: the Multicenter AIDS Cohort Study (MACS, n ¼
522), the Multicenter Hemophilia Cohort Study (MHCS, n ¼
322), the San Francisco City Clinic Cohort (SFCCC, n ¼ 87),
and the AIDS Linked to Intravenous Experience (ALIVE, n ¼
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ers from all the cohorts combined and included all patients
without regard to racial group. Four AIDS-related outcomes
were considered end points of survival analysis: a CD4
þ T
lymphocyte count of less than 200/mm
3 (hereafter termed
‘‘CD4 ,200’’), progression to AIDS according to the 1993
deﬁnition of the CDC (‘‘AIDS 1993’’), progression to AIDS
according to the more stringent 1987 CDC deﬁnition (‘‘AIDS
1987’’), and death. Participants in the Cox model analyses
were stratiﬁed by race and age at seroconversion.
Statistical Analysis
Statistical analysis and graphical presentation was done
using SigmaPlot 5.0 (SPSS, Chicago, Illinois, United States).
Results are given as mean 6 standard deviation (SD) or
median with range. Statistical analysis of signiﬁcance (p-
values) was based on two-tailed t-tests and linear regression
analysis.
Results
Preferential Recognition of a Subset of HIV-1-Specific
CD8
þ T Cell Epitopes during Primary Infection
In order to identify the individual HIV-1-speciﬁc CD8
þ T
cell epitopes targeted during primary infection, as well as
their relative contribution to the entire detectable HIV-1-
speciﬁc CD8
þT cell response, cryopreserved PBMCs from 104
study participants were tested for responses to peptides
corresponding to previously described epitopes for each
person’s respective HLA class I allotypes [26] using an IFN-c
ELISPOT assay. The analysis in this study was restricted to
HLA class I alleles that were expressed in at least three
participants, and for which at least three optimal CD8
þ T cell
epitopes had been described. Table 1 lists the frequencies of
these 21 qualifying HLA class I alleles expressed in the study
population, as well as the number of epitopes tested for each
HLA allele and the percentage of individuals with detectable
CD8
þ T cell responses to the tested epitopic peptides
restricted by the designated allele. The sequences and HLA
class I restrictions of the tested HIV-1 peptides are listed in
Table 2.
Each study participant was tested for CD8
þT cell responses
against a median of 31 epitopic peptides (range 5–53)
reported to be recognized in the context of their expressed
HLA class I alleles, and a median of 3.8 peptides (range 0–20)
induced signiﬁcant IFN-c production of CD8
þ T cells per
participant. The number of epitopes tested per HLA class I
allele did not correlate with the percentage of individuals that
had detectable responses restricted by that allele (Table 1; r¼
0.29, p ¼ 0.2), demonstrating that the differences in the
number of tested peptides per allele did not represent a
major confounding factor for the analysis. Figure 1 summa-
rizes the magnitude of CD8
þT cell responses to the individual
HIV-1-speciﬁc CD8
þ T cell epitopes tested (bars on left of
each graph), as well as the frequency by which they were
recognized in individuals expressing the respective HLA class
I allele (bars on right of each graph). The data demonstrate
clear immunodominance patterns for the majority of HLA
class I alleles, with individual epitopes targeted frequently by
individuals expressing the respective allele, while other
epitopes restricted by the same allele were rarely recognized
in primary infection (Figure 1 and Table 2).
A subanalysis of immunodominance patterns was per-
formed between individuals identiﬁed during acute (69/104)
and early (35/104) HIV-1 infection for those HLA class I
alleles for which at least three individuals were present in
both groups (HLA-A1, -A2, -A3, -A24, -A68, -B7, -B8, -B15, -
B35, -B40, -B44, and -B53, as well as HLA-B57 and -Cw8, for
which only two participants were included in the early
infection group). This analysis demonstrated that the
immunodominant HIV-1-speciﬁc CD8
þ T cell responses were
identical in both acute and early infection for HLA-A1, -A2, -
A24, -B8, -B15, -B40, -B44, -B53, -B57, and -Cw8. For HLA-
A68 and -B35, no HIV-1-speciﬁc CD8
þ T cell responses were
detected in at least one of the two groups. A switch in the
immunodominant HIV-1-speciﬁc CD8
þ T cell responses
between acute and early infection was only observed in the
case of responses restricted by HLA-A3 and HLA-B7. In HLA-
A3, the overlapping p17 Gag epitopes RK9 and RY10
represented the dominant epitopes in acute infection (46%
and 48% of participants targeted these epitopes, respec-
tively), but were targeted only by 29% and 27% of those
identiﬁed during early infection. In contrast, the Nef epitope
QK10 was targeted by 15% of individuals identiﬁed during
acute infection, but the immunodominant epitope in persons
with early infection (43%). This switch in immunodominance
may be the result of sequence evolution within the RK9/RY10
epitopes, or their ﬂanking regions, as described previously
[24]. Finally, the HLA-B7 restricted Env epitope IL9 was
dominant in patients identiﬁed in acute infection (40%), but
less frequently recognized in those with early infection (20%),
while the subdominant epitope-speciﬁc CD8
þ T cell response
directed against the RT SM9 epitope (10% in acute infection)
was the most frequently detected response in the patients
identiﬁed during early infection (50%). However, only ﬁve
participants with early infection, compared to ten with acute
infection, were present in our study cohort, and the differ-
Table 1. HLA Class I Frequencies in Study Population
HLA Class I
Allele
Participants, n
(Frequency, %)
Epitopes
Tested, n
Percentage of Subjects
with Detectable Response
Restricted by Allele
HLA-A2 52 (50) 17 48
HLA-B44 28 (27) 4 28.6
HLA-A1 23 (22) 4 34.8
HLA-A3 23 (22) 18 52.2
HLA-B35 22 (21) 12 40.9
HLA-B8 19 (18) 10 73.7
HLA-A24 15 (14) 6 73.3
HLA-B7 15 (14) 14 66.7
HLA-B40 14 (13) 11 64.3
HLA-A68 13 (12) 5 23.1
HLA-B15 13 (12) 11 53.9
HLA-B18 11 (11) 3 9.1
HLA-A26 9 (9) 3 55.6
HLA-B51 9 (9) 6 77.8
HLA-B57 9 (9) 13 77.8
HLA-A30 8 (8) 8 12.5
HLA-Cw8 8 (8) 4 62.5
HLA-A11 7 (7) 12 85.7
HLA-B53 7 (7) 3 57.1
HLA-B14 5 (5) 4 60.0
HLA-B27 3 (3) 5 100
DOI: 10.1371/journal.pmed.0030403.t001
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þ T Cell Epitopes Tested
HLA Class
I Family
HLA Class
I Allele
Peptide
Number
a
Peptide
Identification
b
Peptide
Sequence
HLA-A HLA-A1 1 A1-RY9 (gp41) RRGWEVLKY
2 A1-IY9 (Rev) ISERILSTY
3 A1-YT9 (Nef) YFPDWQNYT
4 A1-WH10 (Nef) WRFDSRLAFH
HLA-A2 1 A2-FK10 (p1) FLGKIWPSYK
2 A2-SL9 (p17) SLYNTVATL
3 A2-SAV10 (Env) SLLNATAIAV
4 A2-YI9 (RT) YTAFTIPSI
5 A2-AL9 (Vpr) AIIRILQQL
6 A2-PL11 (Nef) PLTFGWCYKL
7 A0205-RA9 (gp41) RIRQGLERA
8 A2-YL9 (p24) YVDRFYKTL
9 A2-LI9 (Pro) LVGPTPVNI
10 A2-IV9 (RT) ILKEPVHGV
11 A2-RI10 (gp120) RGPGRAFVTI
12 A2-VV9 (p24) VLAEAMSQV
13 A2-KL9 (gp160) KLTPLCVTL
14 A2-VL10 (Nef) VLEWRFDSRL
15 A2-RI9 (Vpr) RILQQLLFI
16 A2-AM9 (RT) ALVEICTEM
17 A2-VL9 (RT) VIYQYMDDL
HLA-A3 1 A3-RY11 (p17) RLRPGGKKKY
2 A3-RK9 (p17) RLRPGGKKK
3 A3-QK10 (Nef) QVPLRPMTYK
4 A3-HK9 (Vif) HMYISKKAK
5 A3-AK9 (Nef) AVDLSHFLK
6 A3-ER10 (Rev) ERILSTYLGR
7 A3-KK10 (RT) KLVDFRELNK
8 A3-AK11 (RT) ALVEICTEMEK
9 A3-GK9 (RT) GIPHPAGLK
10 A3-KK9 (p17) KIRLRPGGK
11 A3-RK10 (Vif) RIRTWKSLVK
12 A3-KK11 (Vif) KTKPPLPSVKK
13 A3-RK11 (RT) RMRGAHTNDVK
14 A3-ATK9 (RT) AIFQSSMTK
15 A3-QR9 (RT) QIYPGIKVR
16 A3-TK11 (gp120) TVYYGVPVWK
17 A3-AK10 (Int) AVFIHNFKRK
18 A3-RR11 (gp41) RLRDLLLIVTR
HLA-A11 1 A11-QK10 (Nef) QVPLRPMTYK
2 A11-GK8 (p24) GVGGPGHK
3 A11-AK 11 (p24) ACQGVGGPGHK
4 A11-AK10 (Int) AVFIHNFKRK
5 A11-AK9 (Nef) AVDLSHFLK
6 A11-AK9 (RT) AIFQSSMTK
7 A11-IK10 (RT) IYQEPFKNLK
8 A11-PK8 (Nef) PLRPMTYK
9 A11-QKK9 (RT) QIIEQLIKK
10 A11-QVK9 (RT) QIYAGIKVK
11 A11-SK9 (Env) SVITQACPK
12 A11-TI9 (p17) TLYCVHQRI
HLA-A24 1 A24-RW8 (Nef) RYPLTFGW
2 A24-KW9 (p17) KYKLKHIVW
3 A24-LY10 (gp120) LFCASDAKAY
4 A24-RL11 (p24) RDYVDRFFKTL
5 A24-YL8 (gp41) YLKDQQLL
6 A24-RL9 (gp41) RYLKDQQLL
HLA-A26 1 A26-EL9 (p24) EVIPMFSAL
2 A26-EY9 (Pol) ETKLGKAGY
3 A26-ER11 (RT) ETFYVDGAANR
HLA-A30 1 A30-IY9 (env) IVNRNRQGY
2 A30-KIY9 (RT) KLNWASQIY
3 A30-KQY9 (env) KYCWNLLQY
4 A30-HY9 (gp120) HIGPGRAFY
5 A30-KY9 (INT) KIQNFRVYY
6 A30-KY9 (RT) KQNPDIVIY
7 A30-RV10 (RT) RMRGAHTNDV
8 A30-RY11 (p17) RSLYNTVATLY
Table 2. Continued
HLA Class
I Family
HLA Class
I Allele
Peptide
Number
a
Peptide
Identification
b
Peptide
Sequence
HLA-A68 1 A68-IR11 (Tat) ITKGLGISYGR
2 A68-QV9 (p17) QVSQNYPIV
3 A68-DL9 (RT) DTVLEEMNL
4 A68-IL9 (gp41) IVTRIVELL
5 A68-IV9 (pro) ITLWQRPLV
HLA-B HLA-B7 1 B7-IL9 (gp41) IPRRIRQGL
2 B7-RY10 (Nef) RQDILDLWIY
3 B7-GL9 (p24) GPGHKARVL
4 B7-HI10 (Vif) HPRVSSEVHI
5 B7-SM9 (RT) SPAIFQSSM
6 B7-SV9 (p24) SPRTLNAWV
7 B7-HA9 (Gag) HPVHAGPIA
8 B7-FL9 (Vpr) FPRIWLHGL
9 B7-TM9 (Nef) TPQVPLRPM
10 B7-FL9 (Nef) FPVTPQVPL
11 B7-RI10 (gp120) RPNNNTRKSI
12 B7-RV9 (Nef) RPMTYKAAV
13 B7-TL10 (Nef) TPGPGVRYPL
14 B7-TL9 (p24) TPQDLNTML
HLA-B8 1 B8-FL8 (Nef) FLKEKGGL
2 B8-EI8 (p24) EIYKRWII
3 B8-GK9 (p17) GGKKKYKLK
4 B8-WM8 (Nef) WPTVRERM
5 B8-GL9 (RT) GPKVKQWPL
6 B8-DL9 (p24) DCKTILKAL
7 B8-EV9 (p17) ELRSLYNTV
8 B8-RL9 (gp120) RVKEKYQHL
9 B8-RL9 (gp41) RQGLERALL
10 B8-YL8 (gp41) YLKDQQLL
HLA-B14 1 B14-DA9 (p24) DRFYKTLRA
2 B14-EL9 (gp41) ERYLKDQQL
3 B14-SL9 (Rev) SAEPVPLQL
4 B14-CC9 (p15) CRAPRKKGC
HLA-B15 1 B15-GY9 (p24) GLNKIVRMY
2 B15-WF9 (Nef) WRFDSRLAF
3 B15-RY9 (Int) RKAKIIRDY
4 B15-YL9 (p24) YVDRFFKTL
5 B15-FY10 (Tat) FQTKGLGISY
6 B15-IY10 (RT) IKLEPVHGVY
7 B15-LY12 (RT) LVGKLNWASQIY
8 B15-TY11 (Nef) TQGYFPDWQNY
9 B15-RA9 (Nef) RMRRAEPAA
10 B15-SF9 (gp120) SFNCGGEFF
11 B15-VI10 (Pol) VTDSQYALGI
HLA-B18 1 B18-FK10(p24) FRDYVDRFYK
2 B18-LY10 (Vif) LADQLIHLHY
3 B18-YY9 (Nef) YPLTFGWCY
HLA-B27 1 B27-KK10 (p24) KRWIILGLNK
2 B27-GY10 (gp41) GRRGWEALKY
3 B27-IK9 (p17) IRLRPGGKK
4 B27-RI10 (Nef) RRQDILDLWI
5 B27-RK10 (p24) RRWIQLGLQK
HLA-B35 1 B35-VY8 (Nef) VPLRPMTY
2 B35-DL9 (gp120) DPNPQEVVL
3 B35-NQY9 (RT) NPDIVIYQY
4 B35-HY9 (RT) HPDIVIYQY
5 B35-TY9 (RT) TVLDVGDAY
6 B35-VY10 (RT) VPLDEDFRKY
7 B35-VL11 (gp120) VPVWKEATTTL
8 B35-NIY9 (p24) NPVPVGNIY
9 B35-NY9 (p17) NSSKVSQNY
10 B35-PY9 (p24) PPIPVGDIY
11 B35-TW9 (gp41) TAVPWNASW
12 B35-WF9 (p17) WASRELERF
HLA-B40 1 B40-KL9 (p15) KELYPLTSL
2 B40-KL9 (Nef) KEKGGLEGL
3 B40-IL10 (p17) IEIKDTKEAL
4 B40-RL9 (Vpr) REPHNEWTL
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reach statistical signiﬁcance (B7-IL9, p¼0.6; B7-SM9, p¼0.1).
The results from this subanalysis demonstrate that, although
there was some evidence of ongoing evolution of individual
immune responses from acute to early infection, the
immunodominance patterns of HIV-1-speciﬁc CD8
þ T cell
responses did not differ signiﬁcantly between the 69
individuals identiﬁed during acute HIV-1 infection and the
35 persons identiﬁed during early infection.
In addition to the presence of distinct immunodominant
epitope-speciﬁc CD8
þ T cell responses during primary HIV-1
infection, there was a signiﬁcant tendency for the most
frequently recognized epitopes to represent the epitopes
inducing the strongest CD8
þ T cell responses in terms of
magnitude (Figure 2A). Interestingly, ten epitopes restricted
by seven distinct alleles were recognized by CD8
þ T cells of
more than half of individuals expressing the respective HLA
class I molecule, and all except one HLA-Cw8-restricted
epitope in HIV-1 Nef were restricted by HLA-B alleles, in line
with previous data describing a dominant inﬂuence of HLA-B
alleles in restricting CD8
þ T cell responses in HIV-1 clade C
infection [31]. Taken together, these data demonstrate that
consistent immunodominance patterns can be identiﬁed for
HIV-1-speciﬁc CD8
þ T cell epitopes restricted by common
HLA class I molecules in primary HIV-1 infection, and that
the preferentially targeted epitopes early after infection are
predominantly restricted by HLA-B alleles.
No Differences in Sequence Diversity between Frequently
and Rarely Targeted CD8
þT Cell Epitopes in Primary HIV-1
Infection
We next analyzed the sequence diversity in the frequently
targeted epitopes compared to those that were restricted by
the same HLA class I allele but rarely targeted, since we had
demonstrated previously for selected HIV-1-speciﬁc CD8
þ T
cell epitopes that their sequence heterogeneity in the
circulating HIV-1 strains can be an important determinant
for the ability of the immune system to recognize these
epitopes [24,32–35], whereas some epitopes are only targeted
later in infection despite the presence of the original wild-
type sequence in the initial infecting viral strain [21]. This
more comprehensive analysis in 104 HIV-1 infected individ-
uals identiﬁed during primary infection here demonstrates
that the sequence variability of HIV-1 does not represent a
major determinant for the immunodominance patterns of
detectable epitope-speciﬁc CD8
þ T cell responses directed
against the virus. The degree of conservation between the
immunodominant epitopes targeted by each studied allele
and subdominant epitopes did not differ signiﬁcantly (Figure
2B), suggesting that factors other than just the sequence
variability of the epitope are important in determining the
frequency that epitopes will be targeted.
Immunodomination of Selected HIV-1-Specific CD8
þT Cell
Responses Restricted by Individual HLA Class I Alleles
Each study participant, if fully heterozygous, expressed six
distinct HLA class I alleles, and each of these alleles can
contribute to the total CD8
þ T cell response by presenting
epitopes on the surface of infected cells. We therefore
assessed the contribution of each individual HLA allele to
the total HIV-1-speciﬁc CD8
þ T cell response detected in
individuals expressing the respective allele. As an example,
for each HLA-A1-positive person the relative contribution of
CD8
þ T cell responses against HLA-A1-restricted epitopes to
the total HIV-1-speciﬁc CD8
þ T cell response against all
tested HIV-1 epitopes for the participant’s HLA allotype was
determined; subsequently, the average contribution of HLA-
A1-restricted responses was calculated for all HLA-A1-
positive participants.
Overall, although the differences did not reach statistical
signiﬁcance, there was a trend toward a stronger contribution
of HLA-B-restricted CD8
þ T cell responses to the total early
HIV-1-speciﬁc CD8
þ T cell response compared to HLA-A-
restricted responses (HLA-B, 45% 6 39% versus HLA-A,
35% 6 36%; p ¼ 0.08), in line with the above-described
preferential restriction of frequently targeted epitopes
(.50% of study participants) by HLA-B alleles (9/96 HLA-B
epitopes tested versus 0/73 HLA-A epitopes; p , 0.01). HLA-
C-restricted responses did not contribute signiﬁcantly to the
total detected HIV-1-speciﬁc CD8
þ T cell responses, but the
small number of described HIV-1-speciﬁc CD8
þ Tc e l l
Table 2. Continued
HLA Class
I Family
HLA Class
I Allele
Peptide
Number
a
Peptide
Identification
b
Peptide
Sequence
5 B40-GI9 (p15) GELDRWEKI
6 B40-IL9 (RT) IEELRQHLL
7 B40-SL9 (p24) SEGATPQDL
8 B40-AV9 (p24) AEWDRVHPV
9 B40- KA9 (p24) KETINEEAA
10 B40-QL10 (gp41) QELKNSAVSL
11 B40-TL8 (p15) TERQANFL
HLA-B44 1 B44-AW11 (p24) AEQASQDVKNW
2 B44-AY10 (gp160) AENLWVTVYY
3 B44-RL11 (p24) RDYVDRFYKTL
4 B44-EV9 (p24) EEKAFSPEV
HLA-B51 1 B51-LI9 (Int) LPPVVAKEI
2 B51-EI9 (Vpr) EAVRHFPRI
3 B51-TI8 (RT) TAFTIPSI
4 B51-RL9 (gp41) RAIEAQQHL
5 B51-EI9 (RT) EKEGKISKI
6 B51-LI9(gp160) LPCRIKQII
HLA-B53 1 B53-YY9 (Nef) YPLTFGWCY
2 B53-QW9 (p24) QASQEVKNW
3 B53-EW10 (Tat) EPVDPRLEPW
HLA-B57 1 B57-TW10 (p24) TSTLQEQIGW
2 B57-IW9 (RT) IVLPEKDSW
3 B57-IF9 (Vif) ISKKAKGWF
4 B57-SW10 (INT) STTVKAACWW
5 B57-HW9 (Nef) HTQGYFPDW
6 B57-KF11 (p24) KAFSPEVIPMF
7 B57-AW9 (Vpr) AVRHFPRIW
8 B57-IW9 (p24) ISPRTLNAW
9 B57-KF9 (Int) KTAVQMAVF
10 B57-KI8 (p24) KAFSPEVI
11 B57-KY10 (Rev) KAVRLIKFLY
12 B57-QW9 (p24) QASQEVKNW
13 B57-YT9 (Nef) YFPDWQNYT
HLA-Cw HLA-Cw8 1 Cw8-AL9 (Nef) AAVDLSHFL
2 Cw8-SL9 (Rev) SAEPVPLQL
3 Cw8-RV9 (p24) RAEQASQEV
4 Cw8-TL9 (p24) TPQDLNTML
aPeptide numbers are as they appear for the respective HLA class I alleles in Figure 1.
bPeptide identification provides the restricting HLA class I allele, the first and last amino
acid of the respective epitope, the length of the epitope, and the HIV-1 protein containing
the epitope.
DOI: 10.1371/journal.pmed.0030403.t002
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Immunodominance in Primary HIV Infectionepitopes for these class C alleles [26] may have resulted in an
underestimation of HLA-C-restricted responses, whereas a
similar number of epitopes were tested for HLA-A and HLA-
B (median of 7 epitopes per A allele, range 3–18; median of 8
epitopes per B allele, range 3–14; p ¼ 0.6 [see Table 1]).
In line with previous data [23], HIV-1-speciﬁc CD8
þ T cell
responses restricted by HLA-B57 contributed strongly to the
total virus-speciﬁc immune response, accounting for an
average of 66% of the total response against HIV-1 among
individuals with this allele (Figure 3). HLA-B57 was followed
by HLA-B27, another allele that has been associated with
slower HIV-1 disease progression [27–29,36,37], in percent
contribution to the total HIV-1-speciﬁc CD8
þ T cell response
(Figure 3). The robust contribution of these two alleles was
not due to a higher number of epitopic peptides tested for
these alleles (5 for HLA-B27 and 13 for HLA-B57 compared
to a median of 6, range 3–18 for all the remaining alleles
studied; p¼0.9), but was rather due to dominant responses to
a single epitope in each case (TW10 for B57 and KK10 for
B27, also see Figure 1, which shows a clear dominant response
for each of these alleles).
The dominant effect of HLA-B27 and -B57 in restricting
Figure 1. Immunodominance Patterns for HIV-1-Specific CD8
þ T Cell Responses Restricted by Individual HLA Class I Alleles
Peptides corresponding to described optimal HIV-1-specific CD8
þ T cell epitopes were tested in all study participants expressing the respective HLA
class I allele. The average magnitude of CD8
þ T cell responses specific for each tested peptide, given as SFCs per million input PBMCs (SFC/Mill PBMC),
are shown as bars in the left part of each graph. The percentage of participants expressing the respective allele that had a detectable peptide-specific
CD8
þ T cell response are shown as bars on the right part of each graph. Epitopes are aligned for each HLA class I allele according to their frequency of
recognition from top to bottom. The peptide number corresponds to the peptide sequence listed for each HLA allele and number in Table 2. Data are
shown only for HLA class I alleles that were expressed in at least three individuals, and for which at least three HIV-1-specific optimal CD8
þ T cell
epitopes had been defined.
DOI: 10.1371/journal.pmed.0030403.g001
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Immunodominance in Primary HIV InfectionHIV-1-speciﬁc CD8
þ T cell responses during primary in-
fection was further demonstrated by a signiﬁcant difference
in the contribution of other studied HLA alleles to the total
response in the presence versus absence of HLA-B57 and -
B27. The great diversity of HLA genotypes allowed this
comparison for only a selected number of alleles that were
sufﬁciently frequent in this study cohort. As exempliﬁed in
Figure 4 for the frequently expressed alleles HLA-A1, -A2, -
A3, and -A24, the average contribution of these alleles to the
total virus-speciﬁc CD8
þ T cell response was 13% (HLA-A1),
27% (-A2), 25% (-A3), and 38% (-A24) in the absence of HLA-
B57 and HLA-B27 expression. These contributions decreased
dramatically in the presence of HLA-B57 or HLA-B27 (HLA-
A1, 0%, p¼0.005; -A2, 1%, p , 0.001; -A3, 10%, p¼0.24; and -
A24, 2%, p ¼ 0.006; Figure 4), despite the fact that the same
HLA-A1, -A2, -A3, or -A24 epitopes were tested under both
conditions. This reduction in the relative contribution of
HLA-A1-, -A2-, -A3-, or -A24-restricted HIV-1-speciﬁc CD8
þ
T cell responses was due to reduction in the absolute
magnitude of virus-speciﬁc CD8
þ T cell responses restricted
by these HLA-A alleles in the presence of HLA-B57 and -B27
(Figure 4), and not to a relatively higher magnitude of
responses restricted by the HLA-B alleles. These data suggest
an active immunodomination of HLA-B57 and -B27-re-
stricted CD8
þ T cell responses during primary HIV-1
infection over other HLA allotypes. In contrast to these two
HLA class I alleles, which are associated with slower disease
progression, the presence of other HLA-B alleles frequently
expressed in this study population, such as HLA-B44, -B35, -
B8, and -B7, did not result in a detectable reduction of the
relative or absolute HIV-1-speciﬁc CD8
þ T cell response
restricted by these HLA-A alleles (p . 0.1 for all comparisons,
unpublished data).
Figure 1. Continued
DOI: 10.1371/journal.pmed.0030403.g001
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Immunodominance in Primary HIV InfectionHLA Class I Allele-Specific Relative Hazard for Disease
Progression Correlates Inversely with the Contribution to
the HIV-1-Specific CD8
þ T Cell Response
The above data for HLA-B57 and HLA-B27 demonstrate
that these two alleles, which have been strongly associated
with slower HIV-1 disease progression, contribute substan-
tially to the total HIV-1-speciﬁc CD8
þ T cell response during
primary HIV-1 infection. We next tested whether the
contribution of an individual HLA class I allele to the total
HIV-1-speciﬁc CD8
þ T cell response in primary infection is
associated with the HR for that allele in progression to four
HIV-1 disease outcomes (CD4 ,200, AIDS 1987, AIDS 1993,
and death), using data from four HIV-1 cohorts (MACS,
MHCS, SFCCC, and ALIVE) [27–30]. For all four outcomes,
the contribution of an HLA allele to the HIV-1-speciﬁc CD8
þ
T cell response during primary infection showed a consistent
inverse correlation with the respective HR (Figure 5), and this
inverse correlation trended toward signiﬁcance for the
outcomes AIDS 1987 (p ¼ 0.06), AIDS 1993 (p ¼ 0.07), and
reached signiﬁcance for death (p ¼ 0.045). While the
correlation was strongly driven by HLA-B27 and HLA-B57,
this analysis, which compared two discrete groups of patients,
suggests that the ability of an HLA class I allele to dominate
the HIV-1-speciﬁc T cell responses during primary infection
might have an important impact on its protective role during
the subsequent course of infection.
Discussion
Several studies suggest that innate and adaptive immuno-
logical events occurring during primary HIV-1 infections play
a crucial role in determining the level of viral replication
during the subsequent disease process. The characterization
of the individual epitopes frequently and consistently
targeted by these early and potent virus-speciﬁc CD8
þ T cells
is therefore of major interest both for the identiﬁcation of
highly immunogenic targets for HIV-1 vaccines and for
studies of the mechanisms underlying immunodominance in
HIV-1 infection. Here we demonstrate in a cohort of 104
individuals with primary HIV-1 infection that only a subset of
known CD8
þ T cell epitopes is frequently and consistently
targeted in the initial stages of HIV-1 infection, when viral
load drops on average more than 1,000-fold. We found,
furthermore, that the HLA class I genotype determines the
level of contribution of CD8
þ T cells responses restricted by
individual alleles to the total HIV-1-speciﬁc T cell response.
HLA alleles that contribute strongly to the initial virus-
speciﬁc CD8
þ T cell response represented those alleles
associated with slower HIV-1 disease progression.
Figure 1. Continued
DOI: 10.1371/journal.pmed.0030403.g001
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Immunodominance in Primary HIV InfectionIn the present study we used peptides corresponding to
optimal HIV-1-speciﬁc CD8
þ T cell epitopes to assess their
frequency of recognition during primary HIV-1 infection.
While the use of described optimal cytotoxic CD8
þ T
lymphocyte epitopes within HIV-1 may have resulted in an
underestimation of total HIV-1-speciﬁc T cell responses, this
approach allowed us to identify a subset of immunodominant
epitopes that are very frequently targeted during this early
phase of HIV-1 infection. In contrast, other well-character-
ized epitopes restricted by the same HLA class I alleles and
located within the same HIV-1 proteins were only rarely
recognized, demonstrating consistent immunodominance
patterns of HIV-1-speciﬁc CD8
þ T cell responses during
primary HIV-1 infection. Furthermore, CD8
þT cell responses
in primary infection were directed against a narrow
repertoire of HIV-1 epitopes, suggesting that a limited
number of CD8
þ T cell responses are sufﬁcient to control
HIV-1 replication during the initial phase of infection. While
these data do not allow for direct conclusions regarding the
epitope-speciﬁc CD8
þ T cell responses that need to be
induced by vaccines in order to mediate protective immunity,
they suggest that the presence of broadly directed and strong
HIV-1 CD8
þ T cell responses is not an absolute requirement
for protective immunity.
Little is known about the mechanisms that determine
immunodominant T cell responses in HIV-1 infection, but
several factors—including the intracellular expression levels
of the respective HIV-1 protein, the kinetics by which an
epitope is processed, its binding afﬁnity to the HLA class I
molecule, and the binding afﬁnity of the peptide–HLA class I
complex to the CD8
þT cell receptor and its repertoire—have
been implicated in the shaping of immunodominance
patterns [38,39]. The current study did not allow us to
address the individual contributions of these ‘‘intrinsic’’
factors to the observed hierarchies in epitope-speciﬁc CD8
þT
cell responses. However, we demonstrate here that the
sequence variability within HIV-1 is not a major factor in
determining immunodominance pattern during primary
HIV-1 infection, as frequently targeted epitopes did not
signiﬁcantly differ in their sequence variability within the
HIV-1 population from rarely targeted epitopes restricted by
the same HLA allele within this study cohort. Taken together,
these studies of HIV-1-speciﬁc CD8
þ T cell responses during
primary HIV-1 infection on the single-epitope level resulted
in the identiﬁcation of several immunodominant epitopes
within HIV-1 that are frequently targeted in infected
individuals of Northern European descent.
HLA class I molecules are codominantly expressed on
antigen-presenting cells, such that all six HLA class I allotypes
(if heterozygous for HLA-A, -B, and -C) can present viral
epitopes and theoretically prime virus-speciﬁc CD8
þ T cell
responses. However, epitopic peptides compete for presen-
tation by HLA molecules, and different HLA class I molecules
may differ in their ability to present the respective viral
epitopes on the cell surface. Here we demonstrate that
selected HLA class I molecules contribute signiﬁcantly more
than other HLA class I molecules to the total HIV-1-speciﬁc
CD8
þ T cell response detected during primary infection.
Interestingly, the presence of HLA-B57 and HLA-B27, two
alleles that contributed more than 65% to the total antiviral
CD8
þT cell response among individuals carrying these alleles,
reduced the relative contribution of HIV-1-speciﬁc CD8
þ T
Figure 2. CD8
þ T Cell responses Directed against the Most Frequently
Recognized CD8
þ T Cell Epitopes Were Also of the Highest Magnitude
(A) For each HLA class I allele studied, the four most frequently targeted
HIV-1-specific CD8
þ T cell epitopes were listed according to their
hierarchy (for HLA class I alleles with only three described epitopes, the
fourth value was excluded from the analysis). The average magnitudes of
CD8
þ T cell responses directed against the 1st, 2nd, 3rd, and 4th most
frequently targeted epitope for each allele were calculated (given as
SFCs per million input PBMCs [SFC/Mill PBMC]) and are shown as box
plots. The average magnitude of the most frequently targeted HIV-1-
specific CD8
þ T cell epitopes restricted by each allele were significantly
higher than the average magnitude of the 3rd and 4th most frequently
targeted epitopes, and the respective p-values are provided above the
box plot.
(B) The sequence conservation within targeted CD8
þT cell epitopes does
not contribute significantly to the observed immunodominance patterns
of HIV-1-specific CD8
þ T cell response in primary infection. For each HLA
class I alleles studied, the four most frequently targeted HIV-1-specific
CD8
þ T cell epitopes were listed according to their hierarchy (for HLA
class I alleles with only three described epitopes; the fourth value was
excluded from the analysis). The average sequence conservations, in
comparison to HIV-1 clade B sequences published in the Los Alamos
Database, of the 1st, 2nd, 3rd, and 4th most frequently targeted epitope
for each allele were calculated (given as percent sequence conservation)
and are shown as box plots. The average percentage of sequence
conservation of the four most frequently targeted HIV-1-specific CD8
þ T
cell epitopes restricted by each allele did not differ significantly.
DOI: 10.1371/journal.pmed.0030403.g002
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Immunodominance in Primary HIV InfectionFigure 3. Different HLA Class I Alleles Differ in Their Contribution to the Total HIV-1-Specific CD8
þ T Cell Response
The percentage contribution of HIV-1-specific CD8
þT cell responses restricted by each individual HLA class I allele to the total HIV-1-specific CD8
þT cell
response in individuals expressing the respective allele is shown. HLA class I alleles are listed according to their contribution from left to right. HLA-B57
and HLA-B27 contributed 66% and 65.4%, respectively, to the total HIV-1-specific CD8
þ T cell response in individuals expressing these alleles.
DOI: 10.1371/journal.pmed.0030403.g003
Figure 4. Immunodomination of HLA-B57-
and HLA-B27-Restricted HIV-1-Specific CD8
þ
T Cell Responses
The percent contribution (left graphs) and
the absolute magnitude (right graphs, given
as SFCs per million input PBMCs [SFC/Mill
PBMC]) of HLA-A1-, -A2-, -A3-, and -A24-
restricted HIV-1-specific CD8
þ Tc e l lr e -
sponses in individuals expressing these
HLA class I alleles alone, or in conjunction
with HLA-B57 or HLA-B27, are shown. Each
dot represents data for one individual. The
contribution, as well as the absolute magni-
tude, of HIV-1-specific CD8
þ T cell responses
directed against HLA-A1-, -A2-, and -A24-
restricted CD8
þ T cell epitopes was signifi-
cantly lower in participants that also coex-
pressed HLA-B57 or HLA-B27. The same
trend was observed for HLA-A3, but did
not reach statistical significance. HLA-A1-, -
A2-, -A3-, and -A24-restricted HIV-1-specific
CD8
þ T cell response did not differ between
individuals expressing other frequent HLA
class B alleles, such as HLA-B7, -B8, -B35, or -
B44 (unpublished data).
DOI: 10.1371/journal.pmed.0030403.g004
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Immunodominance in Primary HIV Infectioncell responses restricted by other HLA molecules expressed in
the same individual, as well as the absolute virus-speciﬁc
CD8
þ T cell response restricted by these other alleles. The
large number of persons examined in this study allowed us to
assess the impact of HLA-B27 and -B57 on the HIV-1-speciﬁc
T cell responses restricted by other alleles, but the high HLA
diversity limited this assay to the most frequent alleles,
including HLA-A1, -A2, -A3, and -A24. For all four HLA-A
alleles studied, the magnitude of HIV-1-speciﬁc CD8
þ T cell
responses restricted during primary infection was dramati-
cally lower in the presence of HLA-B27 and -B57, but not in
the presence of other HLA-B alleles. These data suggest a
selective disadvantage of CD8
þ T cell responses restricted by
these alleles in the presence of HLA-B27 and -B57, and is
consistent with the concept of immunodomination by HLA-
B27- and HLA-B57-restricted HIV-1-speciﬁc CD8
þ T cell
responses [38].
Immunodomination in the evolution of dominant virus-
speciﬁc CD8
þ T cell responses, ﬁrst studied in mice, refers to
the ability of CD8
þ T cells speciﬁc for immunodominant
epitopes to suppress the CD8
þ T cell response to subdomi-
nant epitopes. In these mouse studies, it was shown that the
elimination of an immunodominant epitope resulted in the
development of strong CD8
þ T cell responses to otherwise
subdominant epitopes [40–45]. Subsequent studies in humans
demonstrated that immunodominant Epstein-Barr virus- and
cytomegalovirus-speciﬁc CD8
þ T cell responses restricted by
HLA-A2 were reduced in those who coexpressed HLA-B7
[46,47]. Furthermore, simian immunodeﬁciency virus-in-
fected rhesus macaques expressing both Mamu-A*01 and -
A*02 were recently shown to exhibit a signiﬁcant delay in the
development of a CD8
þ T cell response to a Mamu-A*02-
restricted epitope that represented the immunodominant
response in Mamu-A*02
þ macaques in the absence of Mamu-
A*01 expression [48]. Similar to HLA-B27 and -B57, two HLA
alleles associated with slow disease progression in HIV-1-
Figure 5. Correlation between the Contribution of Individual HLA Class I Alleles to the Total HIV-1-Specific CD8
þ T Cell Response during Primary
Infection and the HR for HIV-1 Infection Outcome
The percent contribution of individual HLA class I alleles to the total HIV-1-specific CD8
þ T cell response during primary infection was correlated to the
HR for four different HIV-1 infection outcomes (time to CD4 ,200, time to AIDS 1987, time to AIDS 1993, and time to death) for the respective HLA
alleles.
DOI: 10.1371/journal.pmed.0030403.g005
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Immunodominance in Primary HIV Infectioninfected humans [27–29,36,37], Mamu-A*01 has been asso-
ciated with slower disease progression in simian immunode-
ﬁciency virus-infected macaques [49–53], indicating that
immunodomination by these major histocompatibility com-
plex alleles in macaques and humans may contribute to their
superior ability to control viral replication. Furthermore,
these three alleles, which are associated with slower disease
progression in HIV-1 infection, all restrict a single highly
immunodominant epitope-speciﬁc CD8
þ T cell response
during primary infection (TW10 for B57 [23], KK10 for B27,
and TL8 for Mamu-A*01 [8,51]), suggesting that the combi-
nation of these speciﬁc epitopes in the context of the
restricting major histocompatibility complex class I allele
may be crucial for the described strong antiviral activity.
Further studies will be needed to elucidate the mechanisms
underlying the immunodominance of virus-speciﬁc CD8
þ T
cell responses restricted by these alleles.
We tested directly for an association between the contri-
bution of an individual HLA class I allele to the total virus-
speciﬁc CD8
þ T cell response in primary HIV-1 infection and
its protective effect on disease progression. The average
contribution of each studied HLA class I allele to the total
HIV-1-speciﬁc T cell response detected using optimal CD8
þT
cell epitopes was calculated in the 104 study participants, and
correlated with the HR for the respective alleles for four
different HIV-1 disease outcomes, as determined previously
in the combined MHCS, ALIVE, MACS, and SFCCC cohort
studies [27–30]. For each of the four outcomes considered
(progression to CD4,200, AIDS 1987, AIDS 1992, and death),
the antiviral contribution of an allele was negatively
correlated with its HR, and this inverse correlation was
borderline signiﬁcant for the outcomes AIDS 1987 (p ¼ 0.06),
AIDS 1993 (p¼0.07), and death (p¼0.045). These data suggest
that HLA class I alleles that contribute robustly to the initial
CD8
þ T cell response against HIV-1 delay progression to
AIDS. It is notable that individuals in these different cohorts
of HIV-1 infected participants were grouped according to
low-resolution two-digit HLA class I typing, and this
association was strongly driven by the associations for HLA-
B57, HLA-B51, and HLA-B27. Future studies of larger cohorts
that take high-resolution HLA class I subtypes into account
will be needed to provide greater detail on the contribution
of speciﬁc HLA class I subtypes to the total HIV-1-speciﬁc
CD8
þ T cell response and disease progression.
Takentogether, thesestudiesina largecohortof individuals
with primary HIV-1 infection demonstrate consistent immu-
nodominance patterns of HIV-1-speciﬁc CD8
þ T cell re-
sponses during primary infection and provide a mechanistic
link for the observed protective effect of speciﬁc HLA class I
alleles on HIV-1 disease progression. Understanding the
precise factors that allow epitope-speciﬁc CD8
þ Tc e l l
responses restricted by individual HLA class I alleles to
dominate over other epitopes restricted by the same allele,
as well as over epitope-speciﬁc T cell responses restricted by
other alleles, will require additional studies and be an
importantstepineffortstomodulateantiviralTcellresponses
generated by therapeutic immunizations or vaccinations.
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Background. Nearly 15,000 new HIV infections occur each day. There is
no cure for HIV, and the treatments currently used to prevent people
with HIV from dying are expensive and unavailable to many who need
them. There is also no vaccine to prevent HIV. An effective vaccine would
somehow induce the immune system to prevent the virus from reaching
destructive levels in the body, but how to design such a vaccine is
unknown.
In most people infected with HIV, the immune system doesn’t keep
the AIDS virus in check over the long term. It has been known for a long
time, however, that the body somehow brings the virus under control
within a few weeks following infection, after which, in the absence of
treatment, the amount of virus gradually increases again over time.
Exactly why the amount of virus drops after initial infection is not fully
understood, but there is good evidence that the white blood cells called
CD8 T lymphocytes, which can kill other cells infected with viruses, are at
least partially responsible for initially bringing HIV infection under
control.
In order for a CD8 T lymphocyte to recognize and kill an infected
cell, that cell has to display some part of the infecting virus on its surface.
There are many possible fragments of HIV that can activate CD8 T cells,
although some of these fragments appear more effective than others at
provoking a strong killer response. Also, in order to activate CD8 T cells
the viral fragments must bind to and be presented by a particular kind of
protein called HLA on the surface of the infected cells. There are
hundreds of varieties of HLA in the human population, allowing our
immune systems to recognize many parts of many different viruses.
(Each person can have up to six different kinds of HLA class I on the
surface of his or her cells). A few specific types of HLA have been found
to provide some advantage in keeping the AIDS virus under control,
possibly because they present fragments of the virus that are particularly
good at activating CD8 T cells.
Why Was This Study Done? The researchers wanted to find out
whether specific HLA types and specific protein fragments (peptides) of
the AIDS virus are particularly important in helping CD8 T cells control
HIV. Specifically, they wanted to find out the very earliest protein
fragments recognized, since these might be particularly important in
keeping the virus in check. They also wanted to see if these particular
HLA-peptide combinations might affect the long-term health of people
with HIV infection. Finding specific combinations of peptide and HLA
that give rise to strong control of HIV could help in the design of an
effective AIDS vaccine.
What Did the Researchers Do and Find? The researchers studied CD8 T
cells in blood samples from 104 people in the early stages of HIV
infection. They used DNA analysis to determine which HLA types were
present in each participant, and then chose, from among 173 different
protein fragments of HIV, the peptides that are known to bind to and be
presented by the participant’s HLA types. The ability of these peptides to
activate the participant’s CD8 T cells was measured in the laboratory.
These studies found that for many types of HLA, there were a few
specific viral peptides that triggered most of the CD8 T cell activity found
in early HIV infection, when the amount of virus in the blood is being
lowered by this response. A few types of HLA were found to contribute
more strongly than others to CD8 T-cell activity in early HIV infection.
These same types of HLA are also found in people who tend to remain
healthier for a longer time after becoming infected with HIV.
What Do These Findings Mean? This study provides evidence that
ability of CD8 T cells to keep HIV under control in the first few months
following infection depends on a person’s HLA composition, and that
this early CD8 T cell activity sets the stage for the long-term balance
between the body and the virus. Knowing the particular peptide–HLA
combinations that dominate the early immune response (when the
immune system appears to be bringing the virus under control) might be
of use in designing an HIV vaccine. Because this study was done in
people already infected with HIV, however, it remains unclear whether a
vaccine based on this knowledge would actually prevent new HIV
infection or improve health after infection, even in people with ‘‘good’’
HLA types.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030403.
  The UCSF Center for HIV Information’s HIV InSite includes resources on
HIV immunology and vaccine development
  The Los Alamos Natural Laboratory HIV Molecular Immunology
Database contains information for researchers on HIV peptides, HLA,
and CD8 T cell responses
  The International AIDS Vaccine Initiative (IAVI) Web site provides policy
and scientific information on the global AIDS vaccine effort
  The Massachuetts General Hospital Web site contains information
about their HIV-1 research programs
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